Deans' stroke musings: A vascular-muscle-adiposity phenotype and incident stroke risk in middle-aged and older adults: a multi-cohort study

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, October 26, 2026

A vascular-muscle-adiposity phenotype and incident stroke risk in middle-aged and older adults: a multi-cohort study

Ask your competent? doctor what this means.

A vascular-muscle-adiposity phenotype and incident stroke risk in middle-aged and older adults: a multi-cohort study

Hui Guo a a,1 , Fangping Xiao a,1 , Zhi Cheng d , Lei Wang b,c,* , Qiu Rao Department of Cardiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China b b,** Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, 210002, China c d Department of Pathology, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China Department of Emergency Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

ABSTRACT

Blood pressure, muscle function and central adiposity are routinely measurable but are usually examined as separate risk domains. We analysed harmonised data from the China Health and Retirement Longitudinal Study (CHARLS), the English Longitudinal Study of Ageing (ELSA) and the Health and Retirement Study (HRS) to test whether a rule-based vascular-muscle-adiposity adverse-count phenotype was associated with incident stroke in middle-aged and older adults. The baseline analytic cohort included 40,520 participants, and the incident stroke risk set included 38,795 participants. The phenotype assigned one point for each adverse dimension: high mean arterial pressure, low maximum grip strength and high waist-to-height ratio, defined using cohort- and sex- specific tertiles. Cohort-specific Cox models were pooled by random-effects meta-analysis. During follow-up, 2011 incident strokes occurred. Adjusted hazard ratios per 1-step increase were 1.32 (95% CI 1.22–1.44) in CHARLS, 1.44 (95% CI 1.23–1.68) in ELSA and 1.22 (95% CI 1.14–1.32) in HRS. The pooled hazard ratio per 1- step increase was 1.30 (95% CI 1.20–1.41), and the pooled hazard ratio for 3 versus 0 adverse dimensions was 1.94 (95% CI 1.60–2.36). All-cause mortality associations were less consistent across cohorts. This three- component phenotype may offer a reproducible way to summarise vascular, muscular and adiposity-related susceptibility to incident stroke in later adulthood; it should not be interpreted as a clinical threshold without adjudicated outcome validation.